Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

Summary

\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors

Timeline

Start

2026-02-01

Primary completion

2027-07-31

Completion

2027-12-31

Drugs

Indications